PMID- 26874942
OWN - NLM
STAT- MEDLINE
DCOM- 20160830
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 65
IP  - 4
DP  - 2016 Apr
TI  - Killer-cell immunoglobulin-like receptor genes and ligands and their role in 
      hematologic malignancies.
PG  - 427-40
LID - 10.1007/s00262-016-1806-9 [doi]
AB  - Natural killer (NK) cells are considered crucial for the elimination of emerging 
      tumor cells. Effector NK-cell functions are controlled by interactions of 
      inhibitory and activating killer-cell immunoglobulin-like receptors (KIRs) on NK 
      cells with human leukocyte antigen (HLA) class I ligands on target cells. KIR and 
      HLA are highly polymorphic genetic systems segregating independently, creating a 
      great diversity in KIR/HLA gene profiles in different individuals. There is an 
      increasing evidence supporting the relevance of KIR and HLA ligand gene 
      background for the occurrence and outcome of certain cancers. However, the data 
      are still controversial and the mechanisms of receptor-ligand mediated NK-cell 
      action remain unclear. Here, the main characteristics and functions of KIRs and 
      their HLA class I ligands are reviewed. In addition, we review the HLA and KIR 
      correlations with different hematological malignancies and discuss our current 
      understanding of the biological significance and mechanisms underlying these 
      associations.
FAU - Varbanova, Viktoria
AU  - Varbanova V
AD  - National Specialized Hospital for Active Treatment of Haematological Diseases, 
      Sofia, Bulgaria.
FAU - Naumova, Elissaveta
AU  - Naumova E
AD  - Department of Clinical Immunology and Stem Cell Bank, University Hospital 
      "Alexandrovska", Medical University, 1, Georgi Sofiiski Str., 1431, Sofia, 
      Bulgaria.
FAU - Mihaylova, Anastasiya
AU  - Mihaylova A
AD  - Department of Clinical Immunology and Stem Cell Bank, University Hospital 
      "Alexandrovska", Medical University, 1, Georgi Sofiiski Str., 1431, Sofia, 
      Bulgaria. mihaylova_ap@abv.bg.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160213
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Genetic Predisposition to Disease/genetics
MH  - HLA Antigens/*immunology/metabolism
MH  - Hematologic Neoplasms/genetics/*immunology/metabolism
MH  - Humans
MH  - Killer Cells, Natural/*immunology/metabolism
MH  - Ligands
MH  - Models, Immunological
MH  - Multigene Family/genetics/immunology
MH  - Protein Binding/immunology
MH  - Receptors, KIR/genetics/*immunology/metabolism
PMC - PMC11029164
OTO - NOTNLM
OT  - HLA ligands
OT  - Hematological malignancies
OT  - Killer immunoglobulin-like receptors
OT  - NK cells
COIS- The authors have no conflict of interest to declare.
EDAT- 2016/02/15 06:00
MHDA- 2016/08/31 06:00
PMCR- 2016/02/13
CRDT- 2016/02/15 06:00
PHST- 2015/05/27 00:00 [received]
PHST- 2016/01/29 00:00 [accepted]
PHST- 2016/02/15 06:00 [entrez]
PHST- 2016/02/15 06:00 [pubmed]
PHST- 2016/08/31 06:00 [medline]
PHST- 2016/02/13 00:00 [pmc-release]
AID - 10.1007/s00262-016-1806-9 [pii]
AID - 1806 [pii]
AID - 10.1007/s00262-016-1806-9 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2016 Apr;65(4):427-40. doi: 10.1007/s00262-016-1806-9. 
      Epub 2016 Feb 13.